Hosted on MSN1mon
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride ... The company acquired Onapgo, previously known as SPN-830, from US WorldMeds in 2020.
Nasdaq1mon
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, the First Subcutaneous Apomorphine Infusion Device for Parkinson's Disease in the U.S.
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Supernus will ...
WAVY-TV1mon
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Supernus will ...
The Globe and Mail1mon
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight
Parkinson’s Disease Companies are UCB Biopharma SRL, Novartis, Annovis Bio, Supernus ... SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion ...
manilatimes20d
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by ... President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the ...
manilatimes1mon
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Supernus will make ...